Department of Surgical Oncology and Vascular Surgery, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan.
Gastroenterology. 2016 Dec;151(6):1122-1130. doi: 10.1053/j.gastro.2016.08.002. Epub 2016 Aug 12.
BACKGROUND & AIMS: A random biopsy is recommended for surveillance of ulcerative colitis (UC)-associated colorectal cancer. However, a targeted biopsy might be more effective. We conducted a randomized controlled trial to compare rates of neoplasia detection by targeted vs random biopsies in patients with UC.
We performed a study of 246 patients with UC for 7 years or more, seen at 52 institutions in Japan from October 1, 2008 through December 31, 2010. Patients were randomly assigned to the random group (4 random biopsies collected every 10 cm in addition to targeted biopsies, n = 122) or the target group (biopsies collected from locations of suspected neoplasia, n = 124). The primary end point was the number of neoplastic lesions detected in a single surveillance colonoscopy. We estimated the ratio and difference in the mean number of neoplastic lesions between the groups. We also evaluated the non-inferiority between the groups as an exploratory study. A non-inferiority margin of 0.65 (0.13 of 0.20) was considered for the ratio of the mean number of neoplastic lesions between groups.
The mean number of biopsies found to contain neoplastic tissue per colonoscopy was 0.211 (24 of 114) in the target group and 0.168 (18 of 107) in the random group (ratio of 1.251; 95% confidence interval, 0.679-2.306). The lower limit was above the non-inferiority margin of 0.65. Neoplasias were detected in 11.4% of patients in the target group and 9.3% of patients in the random group (P = .617). Larger numbers of biopsy samples per colonoscopy were collected in the random group (34.8 vs 3.1 in the target group; P < .001), and the total examination time was longer (41.7 vs 26.6 minutes in the target group; P < .001). In the random group, all neoplastic tissues found in random biopsies were collected from areas of the mucosa with a history or presence of inflammation.
In a randomized controlled trial, we found that targeted and random biopsies detect similar proportions of neoplasias. However, a targeted biopsy appears to be a more cost-effective method. Random biopsies from areas without any signs of present or past inflammation were not found to contain neoplastic tissues. Clinical Trial Registry: UMIN000001608.
推荐对溃疡性结肠炎(UC)相关结直肠癌进行随机活检以进行监测。然而,靶向活检可能更有效。我们进行了一项随机对照试验,比较了 UC 患者中靶向活检与随机活检检测肿瘤的发生率。
我们对 2008 年 10 月 1 日至 2010 年 12 月 31 日在日本 52 家机构就诊的 UC 患者进行了为期 7 年或以上的研究。患者被随机分配至随机组(除靶向活检外,每 10 cm 采集 4 个随机活检,n=122)或靶向组(从疑似肿瘤的部位采集活检,n=124)。主要终点是单次结肠镜检查中检测到的肿瘤病变数量。我们估计了两组之间肿瘤病变数量的比值和差异。我们还评估了两组之间的非劣效性作为探索性研究。考虑组间肿瘤病变数量比值的非劣效性界值为 0.65(0.20 的 0.13)。
靶向组中每例结肠镜检查发现的含有肿瘤组织的活检数量为 0.211(124 例中有 24 例),随机组为 0.168(107 例中有 18 例)(比值为 1.251;95%置信区间,0.679-2.306)。下限高于 0.65 的非劣效性界值。靶向组中 11.4%的患者和随机组中 9.3%的患者检测到肿瘤(P=0.617)。随机组中每例结肠镜检查采集的活检样本数量更多(34.8 个 vs 靶向组的 3.1 个;P<0.001),总检查时间更长(41.7 分钟 vs 靶向组的 26.6 分钟;P<0.001)。在随机组中,随机活检中发现的所有肿瘤组织均取自有炎症史或存在炎症的黏膜区域。
在一项随机对照试验中,我们发现靶向活检和随机活检检测到的肿瘤比例相似。然而,靶向活检似乎是一种更具成本效益的方法。从没有任何当前或既往炎症迹象的区域采集的随机活检未发现肿瘤组织。临床试验注册:UMIN000001608。